{"nctId":"NCT01712984","briefTitle":"Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years","startDateStruct":{"date":"2012-10"},"conditions":["Influenza"],"count":3360,"armGroups":[{"label":"QIV ID Vaccine Group","type":"EXPERIMENTAL","interventionNames":["Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation"]},{"label":"TIV ID1 Vaccine Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal"]},{"label":"TIV ID2 Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal"]}],"interventions":[{"name":"Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation","otherNames":["QIV ID"]},{"name":"Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal","otherNames":["Fluzone® Intradermal"]},{"name":"Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal","otherNames":["Fluzone® Intradermal"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 18 through 64 years on the day of inclusion\n* Informed consent form (ICF) has been signed and dated\n* Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria:\n* Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)\n* Participation at the time of trial enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure\n* Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following trial vaccination\n* Vaccination against influenza in the past 6 months\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances\n* History of thrombocytopenia\n* Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily\n* Current alcohol abuse or drug addiction\n* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion\n* Identified as an Investigator or employee of the Investigator or trial center with direct involvement in the proposed trial, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed trial\n* Personal or family history of Guillain-Barré Syndrome\n* Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy, and subjects who have a history of neoplastic disease and who have been disease free for ≥ 5 years.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers Against the Influenza Virus Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route","description":"Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"589","spread":null},{"groupId":"OG001","value":"728","spread":null},{"groupId":"OG002","value":"635","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null},{"groupId":"OG001","value":"413","spread":null},{"groupId":"OG002","value":"447","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"93.5","spread":null},{"groupId":"OG002","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Seroconversion to Influenza Virus Vaccine Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route","description":"Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay. Seroconversion was defined as titer\\< 10 (1/dil) on Day 0 and post injection titer ≥ 40 (1/dil) on Day 28, or titer ≥10 (1/dil) on Day 0 and a ≥4 fold increase in titer (1/dil) on Day 28).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"600","spread":null},{"groupId":"OG001","value":"333","spread":null},{"groupId":"OG002","value":"314","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"608","spread":null},{"groupId":"OG001","value":"326","spread":null},{"groupId":"OG002","value":"314","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"580","spread":null},{"groupId":"OG001","value":"253","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"525","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"235","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Against the Influenza Virus Antigens Before and Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route","description":"Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.3","spread":null},{"groupId":"OG001","value":"65.2","spread":null},{"groupId":"OG002","value":"66.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"589","spread":null},{"groupId":"OG001","value":"728","spread":null},{"groupId":"OG002","value":"635","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null},{"groupId":"OG001","value":"56.5","spread":null},{"groupId":"OG002","value":"55.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null},{"groupId":"OG001","value":"413","spread":null},{"groupId":"OG002","value":"447","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":null},{"groupId":"OG001","value":"24.7","spread":null},{"groupId":"OG002","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"93.5","spread":null},{"groupId":"OG002","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"29.7","spread":null},{"groupId":"OG002","value":"25.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Seroprotection Against Influenza Vaccine Antigens Before (Baseline) and Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route","description":"Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay. Seroprotection was defined as titer ≥ 40 \\[1/dil\\] at baseline and 28 days after vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"672","spread":null},{"groupId":"OG001","value":"334","spread":null},{"groupId":"OG002","value":"353","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1014","spread":null},{"groupId":"OG001","value":"537","spread":null},{"groupId":"OG002","value":"524","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"655","spread":null},{"groupId":"OG001","value":"340","spread":null},{"groupId":"OG002","value":"332","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1008","spread":null},{"groupId":"OG001","value":"526","spread":null},{"groupId":"OG002","value":"519","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"335","spread":null},{"groupId":"OG001","value":"210","spread":null},{"groupId":"OG002","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"923","spread":null},{"groupId":"OG001","value":"464","spread":null},{"groupId":"OG002","value":"351","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"467","spread":null},{"groupId":"OG001","value":"262","spread":null},{"groupId":"OG002","value":"224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"976","spread":null},{"groupId":"OG001","value":"403","spread":null},{"groupId":"OG002","value":"477","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route","description":"Solicited injection site: Pain, Erythema, Swelling, Induration, Ecchymosis, and Pruritus; Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering. Grade 3 injection site: Pain and Pruritus Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis \\>100 mm. Grade 3 systemic reactions: Fever ≥39˚C; Headache, Malaise, Myalgia, and Shivering Significant preventing daily activity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"883","spread":null},{"groupId":"OG001","value":"395","spread":null},{"groupId":"OG002","value":"420","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"607","spread":null},{"groupId":"OG001","value":"279","spread":null},{"groupId":"OG002","value":"269","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"322","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"282","spread":null},{"groupId":"OG001","value":"111","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"548","spread":null},{"groupId":"OG001","value":"257","spread":null},{"groupId":"OG002","value":"278","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"459","spread":null},{"groupId":"OG001","value":"216","spread":null},{"groupId":"OG002","value":"255","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"564","spread":null},{"groupId":"OG001","value":"238","spread":null},{"groupId":"OG002","value":"261","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"862","spread":null},{"groupId":"OG001","value":"372","spread":null},{"groupId":"OG002","value":"374","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":1672},"commonTop":["Injection site Pain","Injection site Pruritus","Injection site Erythema","Headache","Myalgia"]}}}